Chronic Phase Chronic Myeloid Leukemia

Also known as: Chronic phase chronic myeloid leukaemia / Leukemia, Myeloid, Chronic-Phase / Myeloid leukemia, chronic / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Chronic myeloid leukemia / CML / Chronic myelogenous leukaemia / Chronic myelocytic leukaemia / Leukemia myelocytic chronic / Chronic myelogenous leukemia / Leukaemia myelocytic chronic / Chronic granulocytic leukemia / Leukaemias chronic myeloid / Chronic myelocytic leukemia / Chronic granulocytic leukaemia / Chronic myeloid leukaemia / Myeloid leukaemia, chronic

DrugDrug NameDrug Description
DB04868NilotinibA kinase inhibitor used for the chronic phase treatment of Chronic Myeloid Leukemia (CML) that is Philadelphia chromosome positive and for the treatment of CML that is resistant to therapy containing imatinib.
DB08901PonatinibA kinase inhibitor used to treat patients with various types of chronic myeloid leukemia (CML).
DrugDrug NameTargetType
DB04868NilotinibTyrosine-protein kinase ABL1target
DB04868NilotinibMast/stem cell growth factor receptor Kittarget
DB04868NilotinibCytochrome P450 2D6enzyme
DB04868NilotinibCytochrome P450 2C8enzyme
DB04868NilotinibCytochrome P450 2C9enzyme
DB04868NilotinibCytochrome P450 3A4enzyme
DB04868NilotinibP-glycoprotein 1transporter
DB04868NilotinibATP-binding cassette sub-family G member 2transporter
DB04868NilotinibUDP-glucuronosyltransferase 1-1transporter
DB04868NilotinibCytochrome P450 2B6enzyme
DB04868NilotinibSolute carrier organic anion transporter family member 1B1transporter
DB08901PonatinibTyrosine-protein kinase ABL1target
DB08901PonatinibBreakpoint cluster region proteintarget
DB08901PonatinibMast/stem cell growth factor receptor Kittarget
DB08901PonatinibProto-oncogene tyrosine-protein kinase receptor Rettarget
DB08901PonatinibAngiopoietin-1 receptortarget
DB08901PonatinibReceptor-type tyrosine-protein kinase FLT3target
DB08901PonatinibCytochrome P450 3A4enzyme
DB08901PonatinibCytochrome P450 2C8enzyme
DB08901PonatinibCytochrome P450 2D6enzyme
DB08901PonatinibCytochrome P450 3A5enzyme
DB08901PonatinibP-glycoprotein 1transporter
DB08901PonatinibATP-binding cassette sub-family G member 2transporter
DB08901PonatinibFibroblast growth factor receptor 1target
DB08901PonatinibFibroblast growth factor receptor 2target
DB08901PonatinibFibroblast growth factor receptor 3target
DB08901PonatinibFibroblast growth factor receptor 4target
DB08901PonatinibTyrosine-protein kinase Lcktarget
DB08901PonatinibProto-oncogene tyrosine-protein kinase Srctarget
DB08901PonatinibTyrosine-protein kinase Lyntarget
DB08901PonatinibVascular endothelial growth factor receptor 2target
DB08901PonatinibPlatelet-derived growth factor receptor alphatarget
DrugDrug NamePhaseStatusCount
DB04868Nilotinib1Completed1
DB00172Proline1Completed1
DB08877Ruxolitinib1Completed1
DB04868Nilotinib1 / 2Recruiting1
DB08901Ponatinib1 / 2Not Yet Recruiting1
DB08877Ruxolitinib1 / 2Recruiting1
DB01254Dasatinib2Active Not Recruiting2
DB00619Imatinib2Active Not Recruiting1
DB08877Ruxolitinib2Not Yet Recruiting1
DB00135Tyrosine2Not Yet Recruiting1
DB04868Nilotinib3Active Not Recruiting1
DB06300Ponatinib3Active Not Recruiting1
DB08901Ponatinib3Active Not Recruiting1
DB01254Dasatinib4Completed1